Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint

Basch, Ethan M.; Scholz, Mark; de Bono, Johann S.; Vogelzang, Nicholas; de Souza, Paul; Marx, Gavin; Vaishampayan, Ulka; George, Saby; Schwarz, James K.; Antonarakis, Emmanuel S.; O'Sullivan, Joseph M.; Kalebasty, Arash Rezazadeh; Chi, Kim N.; Dreicer, Robert; Hutson, Thomas E.; Dueck, Amylou C.; Bennett, Antonia V.; Dayan, Erica; Mangeshkar, Milan; Holland, Jaymes; Weitzman, Aaron L.; Scher, Howard I.

Published in

Elsevier, European Urology, 6(75), p. 929-937, 2019

DOI: 10.1016/j.eururo.2018.11.033

Tools

Export citation

Search in Google Scholar

Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint

Journal article published in 2019 by Ethan M. Basch, Mark Scholz, Johann S. de Bono, Nicholas Vogelzang, Paul de Souza, Gavin Marx, Ulka Vaishampayan, Saby George

, James K. Schwarz, Emmanuel S. Antonarakis, Joseph M. O'Sullivan, Arash Rezazadeh Kalebasty, Kim N. Chi, Robert Dreicer, Thomas E. Hutson and other authors.

This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Preprint: archiving allowed

Upload

Postprint: archiving restricted

Upload

Published version: archiving forbidden

Policy details

Data provided by

Published in

Links

Tools

Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint